Placeholder Banner

BIO Comments to FDA on Rare Disease Endpoint Advancement Pilot Program Workshop: Novel Endpoints for Rare Disease Drug Development

July 20, 2023

BIO submitted comments on the recent Rare Disease Endpoint Advancement (RDEA) Pilot Program Workshop, held June 7-8, 2023 (Docket No. FDA-2022-N-2480)

Download Full Comments Below
BIO Comments to FDA on Rare Disease Endpoint Advancement Pilot Program Workshop: Novel Endpoints for Rare Disease Drug Development
Discover More
BIO Board Vice Chair and CEO of Amicus Therapeutics testified that the drug price controls in the Inflation Reduction Act harm drug research and development.
BIO joined with other groups in writing House and Senate Agriculture Committee leaders in support of agricultural research (FFAR) funding in the farm bill.